Janson, Christer
Hisinger-Mölkänen, Hanna
Tamasi, Lilla
Vartiainen, Ville
Lehtimäki, Lauri
Funding for this research was provided by:
Orion Corporation
Article History
Received: 9 July 2025
Accepted: 9 September 2025
First Online: 6 October 2025
Declarations
:
: Christer Janson has received honoraria for educational activities and lectures from ALK, AstraZeneca, Chiesi, GlaxoSmithKline, Orion, Sanofi and Stallergenes, and has served on advisory boards arranged by ALK, AstraZeneca, GlaxoSmithKline, Orion, Sanofi and Stallergenes. Hanna Hisinger-Mölkänen is a former employee of Orion Corporation and reports consultation fees from AstraZeneca, Orion, MSD and GSK. Lilla Tamasi has received personal fees for lectures and advisory board meetings from AstraZeneca, Berlin Chemie, Chiesi, Orion and Sanofi. Ville Vartiainen is a former employee of Orion and has since received lecture and consultation fees from Orion Corporation. Lauri Lehtimäki has received personal fees for lectures and advisory board meetings from ALK, AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Chiesi, GSK, Orion and Sanofi.
: This article is based on previously conducted study and does not contain any new studies with human participants. The original clinical study was approved by the Medical Research Council Scientific and Research Ethics Committee of Hungary and all procedures followed their ethical standards, as well as those of the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all study participants prior to study commencement.